Adam Asch to Myelodysplastic Syndromes
This is a "connection" page, showing publications Adam Asch has written about Myelodysplastic Syndromes.
Connection Strength
0.213
-
A randomized phase II/III study of 'novel therapeutics' versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612. Leuk Lymphoma. 2023 02; 64(2):473-477.
Score: 0.213